Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(60%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
40%
Ph phase_1
2
40%
Ph phase_4
1
20%

Phase Distribution

2

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)

Detailed Status

Recruiting3
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 41 (20.0%)

Trials by Status

recruiting360%
completed120%
withdrawn120%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_2

Vinpocetine in Patients With Parkinsonian Disease

NCT07229664
recruitingphase_1

Celecoxib in Parkinson Disease as Adjuvant Therapy

NCT07246278
recruitingphase_2

Metformin in Parkinson Disease

NCT07229651
withdrawnphase_4

Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation

NCT02346630
completedphase_1

Pharmacokinetic Study With Repeated Doses of Stalevo

NCT00693862

Clinical Trials (5)

Showing 5 of 5 trials
NCT07229664Phase 2

Vinpocetine in Patients With Parkinsonian Disease

Recruiting
NCT07246278Phase 1

Celecoxib in Parkinson Disease as Adjuvant Therapy

Recruiting
NCT07229651Phase 2

Metformin in Parkinson Disease

Recruiting
NCT02346630Phase 4

Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation

Withdrawn
NCT00693862Phase 1

Pharmacokinetic Study With Repeated Doses of Stalevo

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5